Key Takeaway From 2-Year Follow-Up Data of ZUMA-1 Trial in Large B-Cell Lymphoma
Sattva S. Neelapu, MD, discusses the main takeaway from 2-year follow-up data from the ZUMA-1 trial looking at axicabtagene ciloleucel in patients with refractory large B-cell lymphoma.
Sattva S. Neelapu, MD, a professor in lymphoma and myeloma at MD Anderson Cancer Center, discusses the main takeaway from 2-year follow-up data from the ZUMA-1 trial looking at axicabtagene ciloleucel (Axi-Cel) in patients with refractory large B-cell lymphoma.
After a median follow-up of 27 months, overall survival (OS) has not been reached. According to Neelapu, this is an almost 4 month increase compared to historical data for traditional therapies where OS is expected to be around 6 months.
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
